We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

150 hedge funds and large institutions have $318M invested in PDL BioPharma, Inc. in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 63 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

206% more call options, than puts

Call options by funds: $459K | Put options by funds: $150K

63% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 16

49% more capital invested

Capital invested by funds: $214M → $318M (+$104M)

7% more funds holding

Funds holding: 140 → 150 (+10)

48% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 63

Holders
150
Holders Change
+10
Holders Change %
+7.14%
% of All Funds
2.96%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
26
Increased
33
Reduced
63
Closed
16
Calls
$459K
Puts
$150K
Net Calls
+$309K
Net Calls Change
+$165K

Top Buyers

1
ECM
Engine Capital Management
New York
+$18M
2
VLKIM
Van Lanschot Kempen Investment Management
Netherlands
+$4.53M
3
NM
Newtyn Management
New York
+$4.35M
4
AA
Ancora Advisors
Ohio
+$3.81M
5
CCM
Context Capital Management
California
+$2.07M

Top Sellers

1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$7.13M
2
Morgan Stanley
Morgan Stanley
New York
-$3.85M
3
Renaissance Technologies
Renaissance Technologies
New York
-$3.47M
4
UBS Group
UBS Group
Switzerland
-$3.45M
5
BCM
Bridgeway Capital Management
Texas
-$2.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
LTFS
126
Ladenburg Thalmann Financial Services
Florida
$10K – – –
TRCT
127
Tower Research Capital (TRC)
New York
$8K -$17.8K -6,147 -70%
CAM
128
ClariVest Asset Management
California
$7K – – –
PHK
129
Point72 Hong Kong
Hong Kong
$7K +$6.55K +2,257 New
Fidelity Investments
130
Fidelity Investments
Massachusetts
$6K +$778 +268 +17%
QI
131
QS Investors
New York
$4K -$393K -135,206 -99%
S
132
SignatureFD
Georgia
$4K -$8.3K -2,861 -67%
FGAM
133
Financial Gravity Asset Management
Texas
$3K -$44 -15 -10%
TL
134
TrueWealth LLC
Georgia
$3K – – –
TWA
135
TCI Wealth Advisors
Arizona
$3K +$255 +88 +11%
US Bancorp
136
US Bancorp
Minnesota
$3K +$1.23K +425 +57%
PNC Financial Services Group
137
PNC Financial Services Group
Pennsylvania
$3K +$2.33K +801 New
Daiwa Securities Group
138
Daiwa Securities Group
Japan
$2K -$607 -209 -25%
FANJ
139
Financial Architects (New Jersey)
New Jersey
$2K – – –
WCG
140
Weaver Consulting Group
California
$2K – – –
QCG
141
Quadrant Capital Group
Ohio
$1K +$920 +317 New
SFS
142
Sowell Financial Services
Arkansas
$1K +$1.06K +364 +428%
BCM
143
Bridgeway Capital Management
Texas
– -$2.1M -971,800 Closed
CM
144
Crestline Management
Texas
– -$1.89M -875,000 Closed
Canada Pension Plan Investment Board
145
Canada Pension Plan Investment Board
Ontario, Canada
– -$401K -185,853 Closed
ECM
146
ExodusPoint Capital Management
New York
– -$223K -103,011 Closed
LI
147
Leap Investments
Illinois
– -$150K -69,496 Closed
DekaBank Deutsche Girozentrale
148
DekaBank Deutsche Girozentrale
Germany
– -$114K -51,900 Closed
Two Sigma Investments
149
Two Sigma Investments
New York
– -$106K -49,093 Closed
Jane Street
150
Jane Street
New York
– -$97K -45,103 Closed
3 4 5
6
7

PDLI Hedge Fund Activity: Q4 2019 in Review

150 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q4 2019, worth a combined $318M — up 49% from $214M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new PDLI positions and 16 closed out — a net gain of 10 holders — while 33 added to existing stakes and 63 trimmed.

The largest buyer was Engine Capital Management, opening a new position worth an estimated $18M. The largest seller was Royal Bank of Canada, cutting an estimated $7.13M.

  • 150 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q4 2019, up from 140 in Q3 2019.
  • Funds reported $318M of PDL BioPharma, Inc. stock for Q4 2019, up 49% quarter-over-quarter.
  • 26 funds opened new PDL BioPharma, Inc. positions in Q4 2019 and 16 closed out, a net change of +10 holders.
  • The largest PDL BioPharma, Inc. buyer in Q4 2019 was Engine Capital Management, an estimated $18M added.
  • The largest PDL BioPharma, Inc. seller in Q4 2019 was Royal Bank of Canada, an estimated $7.13M sold.

Based on aggregated 13F filings for Q4 2019.